Compare Norwegian Cruise Line Holdings Ltd (NCLH) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Norwegian Cruise Line Holdings Ltd vs Pfizer Inc — how do they compare? Norwegian Cruise Line Holdings Ltd trades at $15.5 (market cap $7.11B), while Pfizer Inc trades at $27.72 (market cap $158.56B). The key difference: Pfizer Inc is far larger — about 22.3× Norwegian Cruise Line Holdings Ltd's market cap, and Pfizer Inc pays a 6.18% dividend while Norwegian Cruise Line Holdings Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold Norwegian Cruise Line Holdings Ltd for 68 Days and Pfizer Inc for 158 Days on average.
| NCLH | PFE | |
|---|---|---|
Market Cap | $7.11B | $158.56B |
Volume | 22,683,268 | 44,138,282 |
Sector | Consumer Cyclical | Health |
52-Week High | $25.02 | $29.02 |
52-Week Low | $14.12 | $23.67 |
Typical Hold Time | 68 Days | 158 Days |
Enterprise Value | $21.93B | $210.06B |
Dividend Yield | — | 6.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Norwegian Cruise Line Holdings (NCLH) trades at $15.05, down 2.97% on the day, with a neutral technical signal and bearish moving average trend. The company reported strong earnings beats in recent quarters, with Q3 2026 expected to exceed guidance at $0.914 EPS. Fundamentals show robust revenue growth to $9.83B in 2025, though net income margin compressed to 4.3%. Recent news highlights yield pressure and a $950M senior notes offering.
NCLH presents a mixed outlook: valuation appears attractive with a P/E of 9.39 and analyst consensus target of $20.86, implying upside. However, high debt levels, net yield pressures, and volatile cash flows pose risks. The stock offers potential for recovery if operational improvements and pricing strategies stabilize profitability through 2027.
Pfizer (PFE) trades at $28.00, up 1.87% on the day, with a bullish technical signal from moving averages. The company reported revenue of $62.58 billion in 2025 with a net income margin of 6.8%, and has beaten EPS estimates for the last three quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline as key growth drivers in 2026.
The stock presents a value opportunity with a consensus price target of $29.17, but faces risks from patent expirations and projected earnings decline. Investor sentiment is mixed, with analysts largely neutral, emphasizing the stock's defensive cash flow and dividend yield amid ongoing business transformation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Norwegian Cruise Line Holdings Ltd
Norwegian Cruise Line is the world's third-largest cruise company by berths (at more than 62,000), operating 29 ships across three brands (Norwegian, Oceania, and Regent Seven Seas), offering both freestyle and luxury cruising. The company has redeployed its entire fleet as of May 2022. With eight passenger vessels on order among its brands through 2027 (representing 20,000 incremental berths), Norwegian is increasing capacity faster than its peers, expanding its brand globally. Norwegian sailed to around 500 global destinations before the pandemic.
Read more on NCLH →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
